World Research and Development: NovaLead Pharma Pvt. Ltd. – Product Pipeline Review – H2 2011

• Publication date: June 2012
• Report size: 27 pages

Ltd. - Product Pipeline Review - H2 2011” provides a detailed overview on the NovaLead Pharma Pvt. Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, NovaLead Pharma Pvt. Ltd.’s corporate...

Ltd. - Product Pipeline Review - H2 2011” provides a detailed overview on the NovaLead Pharma Pvt. Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, NovaLead Pharma Pvt. Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from NovaLead Pharma Pvt. Ltd. and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- NovaLead Pharma Pvt. Ltd. - Brief NovaLead Pharma Pvt. Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NovaLead Pharma Pvt. Ltd. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NovaLead Pharma Pvt. Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NovaLead Pharma Pvt. Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate NovaLead Pharma Pvt. Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NovaLead Pharma Pvt. Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NovaLead Pharma Pvt. Ltd.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NovaLead Pharma Pvt. Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NovaLead Pharma Pvt. Ltd. and identify potential opportunities in those areas.

Global Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
November aLead Pharma Pvt. Ltd. Snapshot 5
November aLead Pharma Pvt. Ltd. Overview 5
Key Information 5
Key Facts 5
November aLead Pharma Pvt. Ltd. – Research and Development Overview 6
Key Therapeutic Areas 6
November aLead Pharma Pvt. Ltd. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
November aLead Pharma Pvt. Ltd. – Pipeline Products Glance 11
November aLead Pharma Pvt. Ltd. Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
November aLead Pharma Pvt. Ltd.–Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
November aLead Pharma Pvt. Ltd. – Drug Profiles 14
Galnobax 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
NLP02 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
NLP44 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
NLP61 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
NLP83 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NLP91 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
VLCA04 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
VLCB313 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
VLD01 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
VLD02 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
VLD571 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
VLD631 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
VLDM01 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
VLF02 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
VLI27 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
VLN244 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
November aLead Pharma Pvt. Ltd. – Pipeline Analysis 30
November aLead Pharma Pvt. Ltd. – Pipeline Products by Therapeutic Class 30
November aLead Pharma Pvt. Ltd. - Pipeline Products By Target 31
November aLead Pharma Pvt. Ltd. – Pipeline Products by Route of Administration 32
November aLead Pharma Pvt. Ltd. – Pipeline Products by Molecule Type 33
November aLead Pharma Pvt. Ltd. – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Financial Deals Landscape 35
November aLead Pharma Pvt. Ltd., Deals Summary 35
November aLead Pharma Pvt. Ltd., Pharmaceuticals & Healthcare, Deal Details 36
Venture Financing 36
November aLead Pharma Secures Investment In Series A Venture Financing Round 36
Private Equity 37
Tata Capital Takes Over Stake In November aLead Pharma 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 39
Contact Us 39
Disclaimer 39

List of Tables

November aLead Pharma Pvt. Ltd. – Pipeline by Therapy Area and Indication, H2 2011 8
November aLead Pharma Pvt. Ltd. – Pipeline by Stage of Development, H2 2011 9
November aLead Pharma Pvt. Ltd. – Monotherapy Products in Pipeline, H2 2011 10
November aLead Pharma Pvt. Ltd. - Phase I, H2 2011 11
November aLead Pharma Pvt. Ltd. - Pipeline By Therapeutic Class, H2 2011 30
November aLead Pharma Pvt. Ltd. - Pipeline By Target, H2 2011 31
November aLead Pharma Pvt. Ltd. – Pipeline By Route of Administration, H2 2011 32
November aLead Pharma Pvt. Ltd. – Pipeline By Molecule Type, H2 2011 33
November aLead Pharma Pvt. Ltd., Subsidiaries 34
November aLead Pharma Pvt. Ltd., Deals Summary 35
November aLead Pharma Secures Investment In Series A Venture Financing Round 36
Tata Capital Takes Over Stake In November aLead Pharma 37

List of Figures

November aLead Pharma Pvt. Ltd. – Pipeline by Therapy Area and Indication, H2 2011 7
November aLead Pharma Pvt. Ltd. – Pipeline by Stage of Development, H2 2011 9
November aLead Pharma Pvt. Ltd. – Monotherapy Products in Pipeline, H2 2011 10
November aLead Pharma Pvt. Ltd. – Pipeline By Therapeutic Class, H2 2011 30
November aLead Pharma Pvt. Ltd. - Pipeline By Target, H2 2011 31
November aLead Pharma Pvt. Ltd. – Pipeline By Molecule Type, H2 2011 33